NIH Director Page NIH Health Information Page NIH Impact NIH Fact Sheets NIH Social Media and Outreach
EurekAlert! - National Institutes of Health  
LINKS

Resources

 

NIH Main

 

NIH Research News

 

Funded News

 
  For News & Research
  NIH Videos
  eColumn: NIH Research Matters
  NIH News in Health
  NIH Fact Sheets
 
  Additional Resources
  NIH Home Page
 

About NIH

  NIH Health Information
  Pub Med
  MedlinePlus
  Clinical trials.gov
  More News and Events Sources
  NIH News and Events, Special Interest
 
  RSS Feed RSS Feed
  Back to EurekAlert!
 

 


Department of Health and Human Services

News from the National Institutes of Health

NIH Research News


Key: Meeting M      Journal J      Funder F

Showing releases 1-25 out of 97.

1 | 2 | 3 | 4 > >>

Public Release: 17-Dec-2014
JAMA Psychiatry
Despite risks, benzodiazepine use highest in older people
Prescription use of benzodiazepines -- a widely used class of sedative and anti-anxiety medications -- increases steadily with age, despite the known risks for older people, according to a comprehensive analysis of benzodiazepine prescribing in the United States. Given existing guidelines cautioning health providers about benzodiazepine use among older adults, findings from the National Institutes of Health-funded study raise questions about why so many prescriptions -- many for long-term use -- are being written for this age group.
NIH/National Institute of Mental Health, New York State Psychiatric Institute

Contact: Charlotte Armstrong
nimhpress@mail.nih.gov
301-443-4536
NIH/National Institute of Mental Health

Public Release: 16-Dec-2014
Teen prescription opioid abuse, cigarette, and alcohol use trends down
Use of cigarettes, alcohol, and abuse of prescription pain relievers among teens has declined since 2013 while marijuana use rates were stable, according to the 2014 Monitoring the Future (survey, released today by the National Institute on Drug Abuse. However, use of e-cigarettes, measured in the report for the first time, is high.
NIH/National Institute on Drug Abuse

Contact: NIDA Press Office
media@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse

Public Release: 8-Dec-2014
NIH initiates 'Centers Without Walls' to study sudden unexpected death in epilepsy
Nine groups of scientists will receive funding totaling $5.9 million in 2014 to work together on increasing the understanding of sudden unexpected death in epilepsy, the leading cause of death from epilepsy. The consortium becomes the second Center Without Walls, an initiative to speed the pace of research on difficult problems in epilepsy by promoting collaborative research. The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, funds this initiative.
NIH/National Institute of Neurological Disorders and Stroke

Contact: Barbara McMakin
nindspressteam@ninds.nih.gov
NIH/National Institute of Neurological Disorders and Stroke

Public Release: 4-Dec-2014
Science Translational Medicine
Imaging techniques reliably predict treatment outcomes for TB patients
Two medical imaging techniques, called positron emission tomography and computed tomography, could be used in combination as a biomarker to predict the effectiveness of antibiotic drug regimens being tested to treat tuberculosis patients, according to researchers at NIAID, part of NIH. With multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis on the rise worldwide, new biomarkers are needed to determine whether a particular TB drug regimen is effective.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Emily Mullin
emily.mullin@nih.gov
310-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 4-Dec-2014
American Journal of Psychiatry
Medications for patients with first episode psychosis may not meet guidelines
Many patients with first-episode psychosis receive medications that do not comply with recommended guidelines for first-episode treatment, researchers have found. Current guidelines emphasize low doses of antipsychotic drugs and strategies for minimizing the side effects that might contribute to patients stopping their medication. A NIH-funded study finds that almost 40 percent of people with first-episode psychosis in community mental health clinics across the country might benefit from medication treatment changes.
National Institutes of Health, NIH/National Institute of Mental Health

Contact: Michaelle Scanlon
NIMHpress@mail.nih.gov
301-443-4536
NIH/National Institute of Mental Health

Public Release: 3-Dec-2014
New England Journal of Medicine
NIH researchers link chromosome region to duplication of gene on X chromosome appears to cause excessive growth
Researchers at the National Institutes of Health have found a duplication of a short stretch of the X chromosome in some people with a rare disorder that causes excessive childhood growth. They believe that a single gene within the region likely has a large influence on how much children grow. The research comes from a lab at the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development, which seeks to understand growth.
National Institutes of Health

Contact: Robert Bock or Meredith Daly
dalym@mail.nih.gov
301-496-5133
NIH/National Institute of Child Health and Human Development

Public Release: 3-Dec-2014
Nature
Barrier-breaking drug may lead to spinal cord injury treatments
Injections of a new drug may partially relieve paralyzing spinal cord injuries, based on indications from a study in rats, which was partly funded by the National Institutes of Health
NIH/National Institute of Neurological Disorders and Stroke, Case Western Reserve University Council to Advance Human Health, Mrs. Suzanne Poon, Unite to Fight Paralysis, Brumagin Memorial Fund, Spinal Cord Injury Sucks, United Paralysis Foundation

Contact: Christopher Thomas
thomaschr@ninds.nih.gov
301-496-5751
NIH/National Institute of Neurological Disorders and Stroke

Public Release: 3-Dec-2014
Science Translational Medicine
NIH-led scientists describe new herpes treatment strategy
Scientists have developed a novel treatment approach for persistent viral infections such as herpes. Using animal models of herpes simplex virus infection, researchers show that blocking the activity of a host cell protein called LSD1 reduces herpes infection, shedding and recurrence.
NIH/National Institute of Allergy and Infectious Disease

Contact: Hillary Hoffman
hillary.hoffman@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 1-Dec-2014
PLOS ONE
Sophisticated HIV diagnostics adapted for remote areas
Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers funded by the National Institutes of Health have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1.
NIH/National Institute of Biomedical Imaging and Bioengineering

Contact: Margot Kern
nibibpress@mail.nih.gov
301-496-3500
NIH/National Institute of Biomedical Imaging & Bioengineering

Public Release: 1-Dec-2014
Pediatrics
Nearly 55 percent of US infants sleep with potentially unsafe bedding
Nearly 55 percent of US infants are placed to sleep with bedding that increases the risk of sudden infant death syndrome, or SIDS, despite recommendations against the practice, report researchers at the National Institutes of Health, the Centers for Disease Control and Prevention, and other institutions.
National Institutes of Health

Contact: Robert Bock or Meredith Daly
bockr@mail.nih.gov
301-496-5133
NIH/National Institute of Child Health and Human Development

Public Release: 26-Nov-2014
New England Journal of Medicine
NIAID/GSK experimental Ebola vaccine appears safe, prompts immune response
An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Md.
NIH/National Institute of Allergy and Infectious Disease, GlaxoSmithKline

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 25-Nov-2014
Nature
NIH scientists determine how environment contributes to several human diseases
Using a new imaging technique, National Institutes of Health researchers have found that the biological machinery that builds DNA can insert molecules into the DNA strand that are damaged as a result of environmental exposures. These damaged molecules trigger cell death that produces some human diseases, according to the researchers. The work, appearing online Nov. 17 in the journal Nature, provides a possible explanation for how one type of DNA damage may lead to cancer, diabetes, hypertension, cardiovascular and lung disease, and Alzheimer's disease.
NIH/National Institute of Environmental Health Sciences

Contact: Robin Arnette
arnetter@niehs.nih.gov
919-541-5143
NIH/National Institute of Environmental Health Sciences

Public Release: 24-Nov-2014
JAMA Internal Medicine
Starting treatment soon after HIV infection improves immune health, study finds
In many countries outside the United States, decisions on when to start treatment for HIV infection are based on the level of certain white blood cells called CD4+ T cells, which are commonly measured to determine immune health. A study by NIH grantees suggests that the best time to start treatment also should be based on how much time has elapsed since becoming HIV-infected.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Laura S. Leifman
laura.sivitz@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 19-Nov-2014
Nature
New view of mouse genome finds many similarities, striking differences with human genome
Looking across the genomes of humans and mice, scientists have found that, in general, the systems that are used to control gene activity in both species have many similarities, along with crucial differences. The results may offer insights into gene regulation and other systems important to mammalian biology, and provide new information to determine when the mouse is an appropriate model to study human biology and disease. They may also help explain its limitations.
National Institutes of Health

Contact: Steven Benowitz
steven.benowitz@gmail.com
301-451-8325
NIH/National Human Genome Research Institute

Public Release: 19-Nov-2014
HHS and NIH take steps to enhance transparency of clinical trial results
The US Department of Health and Human Services today issued a Notice of Proposed Rulemaking, which proposes regulations to implement reporting requirements for clinical trials that are subject to Title VIII of the Food and Drug Administration Amendments Act of 2007.

Contact: NIH Office of Communications
nihnmb@mail.nih.gov
301-496-5787
NIH/Office of the Director

Public Release: 17-Nov-2014
NIH-sponsored study identifies superior drug regimen for preventing mother-to-child HIV transmission
For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during labor and two more after giving birth, an international clinical trial has found.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Laura S. Leifman
laura.sivitz@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 15-Nov-2014
ASN Kidney Week 2014
New England Journal of Medicine
Two drugs are no more effective than 1 to treat common kidney disease
Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health. One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment.

Contact: Krysten Carrera
NIDDKMedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Public Release: 12-Nov-2014
Nature Communications
NIDA researchers confirm important brain reward pathway
Details of the role of glutamate, the brain's excitatory chemical, in a drug reward pathway have been identified for the first time. This discovery in rodents -- published today in Nature Communications -- shows that stimulation of glutamate neurons in a specific brain region leads to activation of dopamine-containing neurons in the brain's reward circuit.
NIH/National Institute on Drug Abuse Intramural Research Program

Contact: NIDA Press Office
media@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse

Public Release: 12-Nov-2014
JAMA Psychiatry
Soldiers at increased suicide risk after leaving hospital
US Army soldiers hospitalized with a psychiatric disorder have a significantly elevated suicide risk in the year following discharge from the hospital, according to research from the Army Study to Assess Risk and Resilience in Servicemembers. The yearly suicide rate for this group, 263.9 per 100,000 soldiers, was far higher than the rate of 18.5 suicides per 100,000 in the Regular Army for the same study period, the study found.
NIH/National Institute of Mental Health

Contact: Michaelle Scanlon
NIMHpress@nih.gov
301-443-4536
NIH/National Institute of Mental Health

Public Release: 6-Nov-2014
Lancet
New drug for common liver disease improves liver health
An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the National Institutes of Health. The FLINT study found that people with nonalcoholic steatohepatitis who took obeticholic acid had improved liver health during that period, including decreased inflammation and fat in the liver and decreased body weight versus people receiving a placebo. OCA was also associated with increases in itching and total cholesterol.

Contact: Media Office
NIDDKMedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Public Release: 6-Nov-2014
Environmental Health Perspectives
Diversity Outbred mice better predict potential human responses to chemical exposures
A genetically diverse mouse model is able to predict the range of response to chemical exposures that might be observed in human populations, researchers from the National Institutes of Health have found. Like humans, each Diversity Outbred mouse is genetically unique, and the extent of genetic variability among these mice is similar to the genetic variation seen among humans.
NIH/National Institute of Environmental Health Sciences, NIH/National Institute of General Medical Sciences

Contact: Robin Mackar
rmackar@niehs.nih.gov
919-541-0073
NIH/National Institute of Environmental Health Sciences

Public Release: 30-Oct-2014
NIMH creates new unit to support its research domain criteria initiative
A new effort by the National Institutes of Health will facilitate communication among scientists, clinicians, and the public to reframe mental health research, from diagnosis to treatment. The Research Domain Criteria unit was recently established by the National Institute of Mental Health, part of NIH, to support the development of the institute's RDoC initiative.

Contact: Keri Chiodo
NIMHPress@nih.gov
301-443-4536
NIH/National Institute of Mental Health

Public Release: 30-Oct-2014
HIV Research for Prevention (HIV R4P) Conference
Model by NIH grantees explains why HIV prevention dosing differs by sex
A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex. This finding helps explain why two large clinical trials testing HIV pre-exposure prophylaxis, or PrEP, in women failed to show efficacy.
NIAID

Contact: Laura S. Leifman
laura.sivitz@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 29-Oct-2014
Nature
Researchers uncover new evidence revealing molecular paths to autism
In the largest study of its kind, researchers used DNA sequencing to uncover dozens of genes that heighten autism risk. Scientists examined more than 14,000 DNA samples from affected children, parents and others, identifying changes in 107 genes that likely contribute to the risk for autism spectrum disorder. The findings provide a better understanding of genetic and cellular changes in pathways and processes possibly involved in ASD, and eventually may help lead to potential therapies.
National Institutes of Health

Contact: Steven Benowitz
steven.benowitz@nih.gov
301-451-8325
NIH/National Human Genome Research Institute

Public Release: 28-Oct-2014
NIH-led study explores prevention of heart disease in HIV-infected people
The National Institutes of Health has launched a clinical trial to assess the effects of aspirin and cholesterol-lowering drugs, or statins, on preventing cardiovascular disease in people with long-term HIV infections. This group, which includes people on antiretroviral therapy as well as 'elite controllers' who can limit the virus without antiretroviral therapy, have a higher risk of developing heart disease and stroke compared to the general population.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Linda Huynh
linda.huynh@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Showing releases 1-25 out of 97.

1 | 2 | 3 | 4 > >>

     
   

HOME    DISCLAIMER    PRIVACY POLICY    CONTACT US
Copyright ©2014 by AAAS, the science society.